Searched for
GREVLIMID IMPACT
Dr Reddy's shares in focus after Q4 net profit tumbles 86% YoY; Morgan Stanley, Goldman Sachs weigh inDr. Reddy's Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared w...- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- India Inc eyes best earnings growth in 2 years, but 9 companies may see over 50% profit fall in Q3India Inc anticipates its strongest earnings growth in two years. However, several companies are expected to face significant profit declin...
- Can US generics momentum and CDMO strength keep pharma earnings steady this quarter?Indian pharmaceutical companies are set for a steady September quarter. Growth in the US generics market and domestic sales will drive perf...
- Cipla Q1 results preview: Muted US sales to hit revenue YoY. 4 things to watch out forCipla's June quarter earnings are anticipated to reveal a mixed performance, with robust India sales partially offsetting challenges in the...
- Banking and IT show muted growth, pharma thrives in March quarter resultsMarch quarter results reveal mixed performance across sectors. Banking and IT experienced muted profit growth, while pharma demonstrated st...
- Stocks to buy today: MOSL upgrades Aurobindo Pharma to buy; Nuvama sees over 30% upside in DRLChoice Broking maintains a positive outlook on Mahindra & Mahindra (M&M), citing its dominant position in the SUV and tractor markets and r...
- Capacity push and new drugs critical for Aurobindo's healthA delay in drug approvals in the US market remains a concern for Aurobindo. The company stated that eight ANDAs (abbreviated new drug appli...
- Dr Reddy's Labs shares up 3% after Q2 results. What should investors do?Dr. Reddy's Labs reported a 15% decline in Q2 net profit, despite a 17% rise in revenue driven by global generics. While analysts acknowled...
- Cipla Q2 results preview: 3-6% revenue uptick seen, net profit may rise by up to 5.7%Cipla is set to report a 3-6% revenue growth for the September quarter, as forecasted by four brokerages. The earnings for Q2FY25 will be a...
- Zydus Lifesciences shares fall 6%, brokerages neutral on Sterling Biotech dealZydus Lifesciences Share Price: Zydus Lifesciences' shares fell 6% to Rs 1,109 after acquiring a 50% stake in Sterling Biotech for Rs 550 c...
- Cipla Q1 results preview: PAT may grow 6.5-14% YoY, up to 10% growth seen in revenueCipla reported Q1FY25 net profit expected between Rs 1,061-1,135 crore, with YoY growth of 6.5%-14%. Revenue estimated at Rs 6,749-6,879 cr...
- Dr Reddy's shares rise 4% on Q3 PAT jump but brokerages remain unmoved. Here's whyThe drug maker on Tuesday reported an 11% year-on-year (YoY) jump in net profit at Rs 1,379 crore for the quarter ended December 31, 2023, ...
- Sun facing some clouds is still a buy for analystsShares declined nearly 2.5% in Monday's trading before recouping most of its losses. The stock eventually closed at ₹968.50, down 0.14% fro...
- Hold Dr. Reddy's Laboratories, target price Rs 5100: Sharekhan by BNP ParibasDr. Reddy's Laboratories, incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 73305.57 Crore) operating in Pha...
- Dr Reddy's tumbles 7% post Q4 results! Here's what brokerages recommendDr Reddy's Laboratories reported an 890% YoY surge in March quarter profit at Rs 960.1 crore but shares tumbled nearly 7% to Rs 4,545 in Th...
- Hot Stocks: Brokerages on TCS, Sun Pharma, HPCL, ONGC and Oil IndiaJPMorgan maintained an underweight rating on TCS with a target price of Rs 2700. TCS Q4 missed expectations across the board led by US weak...
- Buy Sun Pharmaceutical Industries, target price Rs 1180: JM FinancialSun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 254653.42 Crore) opera...
- Buy Dr. Reddy's Laboratories, target price Rs 7685: JM FinancialDr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 70323.83 Crore) operating i...
- Buy Dr. Reddy's Laboratories, target price Rs 5600: Axis SecuritiesDr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 77528.53 Crore) operating i...
Load More
